castle trial remission data

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial: 7 Reasons Chronic Disease M

7 Reasons Chronic Disease Management Fails Patients

Thirty percent of patients with refractory autoimmune hemolytic anemia achieve durable remission after CD19 CAR-T therapy, yet most chronic disease management programmes still fail to deliver lasting relief. The gap stems from reliance on costly drugs, limited monitoring and a lack of personalised options. Medical Disclaimer: This article is for